Zoetis (ZTS) revenue breakdown
By product, Companion Animal is the largest at 70% of fiscal 2025 revenue, growing 15% a year over 8 years.
By region, Total Geographical Area is the largest at 99% of fiscal 2020 revenue, growing 7% a year over 1 years.
Revenue by product
Fiscal years, as Zoetis reports them in its 10-K filings; fiscal 2025 total $9.5B.
| Products | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|---|---|---|
| Companion Animal | $2.2B | $2.6B | $3.1B | $3.7B | $4.7B | $5.2B | $5.6B | $6.3B | $6.6B | 70% |
| Livestock | $3.0B | $3.2B | $3.0B | $2.9B | $3.0B | $2.8B | $2.9B | $2.9B | $2.8B | 29% |
| Contract Manufacturing and Human Health Diagnostics | $44M | $58M | $85M | $83M | $82M | $86M | $78M | $80M | $116M | 1% |
Revenue by region
Fiscal years, as Zoetis reports them in its 10-K filings; fiscal 2020 total $6.7B.
| Regions | 2019 | 2020 | Share |
|---|---|---|---|
| Total Geographical Area | $6.2B | $6.6B | 99% |
| ITALY | — | $90M | 1% |
| CHILE | $91M | — | — |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for ZTS.
Open ZTS in InvestinglyQuestions
Where does Zoetis make its money?
In fiscal 2025, by product: Companion Animal $6.6B, Livestock $2.8B, Contract Manufacturing and Human Health Diagnostics $116M.
From Zoetis's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.